Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 10/10/2024 | $98.00 → $105.00 | Sector Perform → Outperform | RBC Capital Mkts |
| 8/21/2024 | $92.00 → $94.00 | Perform | Oppenheimer |
| 8/15/2024 | $76.00 → $90.00 | Sell → Neutral | UBS |
| 8/14/2024 | $100.00 → $85.00 | Buy → Hold | Stifel |
| 5/30/2024 | $83.00 | Sell | Goldman |
| 7/19/2023 | $90.00 | Neutral | Robert W. Baird |
| 6/30/2023 | $106.00 | Buy | CL King |
| 5/30/2023 | $104.00 | Equal-Weight → Overweight | Morgan Stanley |
RBC Capital Mkts upgraded Medtronic from Sector Perform to Outperform and set a new price target of $105.00 from $98.00 previously
Oppenheimer reiterated coverage of Medtronic with a rating of Perform and set a new price target of $94.00 from $92.00 previously
UBS upgraded Medtronic from Sell to Neutral and set a new price target of $90.00 from $76.00 previously
4 - Medtronic plc (0001613103) (Issuer)
4 - Medtronic plc (0001613103) (Issuer)
4 - Medtronic plc (0001613103) (Issuer)
SC 13G/A - Medtronic plc (0001613103) (Subject)
SC 13G/A - Medtronic plc (0001613103) (Subject)
SC 13G/A - Medtronic plc (0001613103) (Subject)
8-K - Medtronic plc (0001613103) (Filer)
144 - Medtronic plc (0001613103) (Subject)
8-K - Medtronic plc (0001613103) (Filer)
Delivering durable revenue growth with strong earnings power; strength in Pulsed Field Ablation, Pacing, Structural Heart, Diabetes, and Neuromodulation GALWAY, Ireland, Feb. 18, 2025 /PRNewswire/ -- Medtronic plc (NYSE:MDT) today announced financial results for its third quarter (Q3) of fiscal year 2025 (FY25), which ended January 24, 2025. Key Highlights Revenue of $8.3 billion increased 2.5% as reported and 4.1% organicGAAP diluted EPS of $1.01 increased 2%; non-GAAP diluted EPS of $1.39 increased 7%Company reiterates full year revenue and EPS guidanceCardiac Ablation Solutions revenue increased low-20s on strength of pulsed field ablation (PFA) productsU.S. Centers for Medicare and Medic
GALWAY, Ireland, Feb. 5, 2025 /PRNewswire/ -- Medtronic plc (NYSE:MDT), a global leader in healthcare technology, today announced that it will report financial results for its third quarter of fiscal year 2025 on Tuesday, February 18, 2025. A news release will be issued at approximately 5:45 a.m. Central Standard Time (CST) and will be available at https://news.medtronic.com. The news release will include summary financial information for the company's third quarter of fiscal year 2025, which ended on Friday, January 24, 2025. Medtronic will host a video webcast at 7:00 a.m. CST on February 18, 2025, to discuss results for its third quarter of full fiscal year 2025. The webcast can be access
Medical device industry veteran brings over three decades of expertise in M&A, as well as structured research and development ("R&D") collaborations aligned with Orchestra BioMed's partnership-enabled business model Mr. Cleary previously served as Senior Vice President ("SVP") of Corporate Development at Medtronic plc (NYSE:MDT) ("Medtronic"), where he played a key role in establishing the strategic collaboration between Orchestra BioMed and Medtronic for atrioventricular interval modulation ("AVIM") therapy in hypertension with increased cardiovascular riskEric A. Rose, M.D. to transition from Board Member to Board Member Emeritus and Strategic Advisor, continuing to provide invaluable expe
Delivering durable revenue growth with strong earnings power; strength in Pulsed Field Ablation, Pacing, Structural Heart, Diabetes, and Neuromodulation GALWAY, Ireland, Feb. 18, 2025 /PRNewswire/ -- Medtronic plc (NYSE:MDT) today announced financial results for its third quarter (Q3) of fiscal year 2025 (FY25), which ended January 24, 2025. Key Highlights Revenue of $8.3 billion increased 2.5% as reported and 4.1% organicGAAP diluted EPS of $1.01 increased 2%; non-GAAP diluted EPS of $1.39 increased 7%Company reiterates full year revenue and EPS guidanceCardiac Ablation Solutions revenue increased low-20s on strength of pulsed field ablation (PFA) productsU.S. Centers for Medicare and Medic
GALWAY, Ireland, Dec. 5, 2024 /PRNewswire/ -- The board of directors of Medtronic plc (NYSE:MDT) on Thursday, December 5, 2024, approved the company's cash dividend for the third quarter of fiscal year 2025 of $0.70 per ordinary share. This quarterly declaration is consistent with the dividend increase announcement made by the company in May 2024. Medtronic is a constituent of the S&P 500 Dividend Aristocrats index, having increased its annual dividend payment for the past 47 consecutive years. The dividend is payable on January 10, 2025, to shareholders of record at the close of business on December 27, 2024. About MedtronicBold thinking. Bolder actions. We are Medtronic. Medtronic plc, hea
Delivering on commitments, executing ahead of expectations, and raising guidance Innovation driving sustained growth across many franchises: TAVR, PFA, Leadless Pacemakers, Diabetes, Spine, and Neuromodulation GALWAY, Ireland, Nov. 19, 2024 /PRNewswire/ -- Medtronic plc (NYSE:MDT) today announced financial results for its second quarter (Q2) of fiscal year 2025 (FY25), which ended October 25, 2024. Key Highlights Revenue of $8.4 billion increased 5.3% as reported and 5.0% organicGAAP diluted earnings per share (EPS) of $0.99; non-GAAP diluted EPS of $1.26Company raises FY25 organic revenue growth and EPS guidanceFinancial ResultsMedtronic reported Q2 worldwide revenue of $8.403 billion, an
Medical device industry veteran brings over three decades of expertise in M&A, as well as structured research and development ("R&D") collaborations aligned with Orchestra BioMed's partnership-enabled business model Mr. Cleary previously served as Senior Vice President ("SVP") of Corporate Development at Medtronic plc (NYSE:MDT) ("Medtronic"), where he played a key role in establishing the strategic collaboration between Orchestra BioMed and Medtronic for atrioventricular interval modulation ("AVIM") therapy in hypertension with increased cardiovascular riskEric A. Rose, M.D. to transition from Board Member to Board Member Emeritus and Strategic Advisor, continuing to provide invaluable expe
Inogen, Inc. (Nasdaq: INGN), a medical technology company offering innovative respiratory products for use in the homecare setting, today announced the appointment of Mira Kirti Sahney to Inogen's Board of Directors, effective January 31, 2025. The company also announced that Tom West, who has served as a director since April 2023, retired as a member of the Board of Directors, effective January 30, 2025. "We are thrilled to welcome Mira Sahney to the Inogen Board. Mira brings considerable management, technical, and operational experience in the medical device field to Inogen," said Elizabeth Mora, Chairperson of the Board. "Mira's appointment will further strengthen Inogen's Board with a
GALWAY, Ireland, Jan. 21, 2025 /PRNewswire/ -- Medtronic plc (NYSE: MDT), a global leader in healthcare technology, today announced that Thierry Piéton has been appointed Chief Financial Officer for the company, effective March 3, 2025. He will report to Medtronic Chairman and Chief Executive Officer Geoff Martha and will join the Medtronic Executive Committee. Piéton joins Medtronic from Renault Group, where he has served as Chief Financial Officer since March 2022. Gary Corona, who has been serving as interim CFO, will continue in this role until Piéton joins Medtronic, after which Corona will become Senior Vice President, Corporate Finance and will remain on the Medtronic Executive Commit